Tofacitinib
Cross-source consensus on Tofacitinib from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Comparisons
Highlighted claims
- Tofacitinib is a Janus kinase inhibitor with efficacy and safety demonstrated in randomized controlled trials as both monotherapy and in combination with methotrexate. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- The probability of remaining on tofacitinib at 24 months was 48%, with a mean treatment persistence of 524 days. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- By Clinical Disease Activity Index, low disease activity increased from 13% at baseline to 75% at month 24 among patients still receiving tofacitinib. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Drug survival was similar between tofacitinib monotherapy and tofacitinib plus MTX. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Real-world tofacitinib drug survival was lower than estimates from long-term extension studies of randomized trials because those enrolled patients pre-selected for acceptable efficacy and tolerability. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)